The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 447.50
Bid: 440.00
Ask: 455.00
Change: 0.00 (0.00%)
Spread: 15.00 (3.409%)
Open: 447.50
High: 447.50
Low: 447.50
Prev. Close: 447.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

19 Dec 2023 07:00

RNS Number : 1950X
Tristel PLC
19 December 2023
 

Tristel plc

("Tristel", the "Company", or the "Group")

AGM Statement, notice of results and planned CEO succession

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, will hold its Annual General Meeting at 11am today at the offices of Cavendish, One Bartholomew Close, London EC1A 7BL.

 

Paul Swinney, Chief Executive Officer, will address the meeting with the following update:

 

"I am pleased to report that the Company has had a record first half with revenue for the six months ending 31 December 2023 expected to be £20.7m, an increase of 18% compared to £17.5m in the first half of last year. Revenue growth has been delivered across all our geographical markets. Gross margin remains above 80% in line with our expectations.

 

"In the United States, Parker Laboratories, our manufacturing and distribution partner, completed its first production run for Tristel ULT in early October, following receipt of our FDA approval in June 2023. This has enabled Parker to stock its national distribution network and provide product to the first beta site users. We expect to make steady progress in building our customer base throughout the United States during the second half of our financial year. We remain very excited about our prospects as we begin serving the largest healthcare market in the world.

 

"The business is performing strongly on all fronts and the confidence that we expressed in October in our medium-term outlook remains unchanged. With the growth possibilities for our business stronger than ever, and as a business with no debt and forecast cash balances of approximately £10.4m after payment of this year's final dividend on 22 December, we are in a strong position to capitalise upon our global leadership position in the medical device decontamination market." 

 

Notice of Results

The Company's unaudited interim results will be announced on 26 February 2024.

 

CEO succession planning

In addition, Paul Swinney, co-founder of the business in 1993 and Group CEO for the past thirty years, has informed the Board of his intention to retire within the next twelve months. Paul will continue in his post until a successor is appointed and has committed to remain available thereafter to support and advise the business in executing a successful transition in the leadership of the Group. The Board has, therefore, initiated a formal succession process, supported by the global organisational consulting firm The Coulter Partnership, that will consider both external and internal candidates.

 

The Group's new CEO will join a strong executive leadership team with significant functional and market experience, gained from within and outside the business.

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Chief Financial Officer

 

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Charlotte Edgar

Mob: 07884 664 686

Alice Woodings

Mob: 07407 804 654

Cavendish Capital Markets Limited

Tel: 020 7220 0500

Geoff Nash/Charlie Beeson (Corporate Finance)

Sunila de Silva (ECM)

 

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMEVLFFXLLXFBL
Date   Source Headline
5th Jul 20177:00 amRNSIssue of Equity
3rd Jul 20171:59 pmRNSStrategic investment
3rd Jul 20177:00 amRNSSubmission to EPA & subsidiary incorporated in USA
13th Jun 20177:00 amRNSIssue of Equity
24th May 20177:00 amRNSShareholder Open Day & Notice of Trading Update
19th May 20173:34 pmRNSIssue of Equity
3rd May 20178:27 amRNSIssue of Equity
7th Apr 20175:04 pmRNSResult of Placing
7th Apr 20172:07 pmRNSProposed Secondary Placing
28th Mar 20172:38 pmRNSIssue of Equity
7th Mar 20179:41 amRNSIssue of Equity
6th Mar 20177:00 amRNSIssue of Equity
27th Feb 20177:00 amRNSProducts approved by Australia's TGA
27th Feb 20177:00 amRNSJournal of Ultrasound in Medicine & Biology
23rd Feb 20177:00 amRNSHalf-year Report
25th Jan 20177:00 amRNSInvestor results presentation
24th Jan 20177:00 amRNSJournal of Infection Prevention: TSTL wipes study
17th Jan 201712:31 pmRNSDirector / PDMR Shareholding
13th Dec 201612:30 pmRNSResult of AGM
13th Dec 20167:00 amRNSAGM Statement
6th Dec 20167:00 amRNSIssue of Equity
28th Nov 20163:42 pmRNSNotice of AGM correction
23rd Nov 201612:37 pmRNSIssue of Equity
17th Oct 20167:00 amRNSFinal Results
13th Oct 20168:33 amRNSIssue of Equity
12th Oct 20168:12 amRNSStudy shows Tristel Wipes System benefits
11th Oct 20167:00 amRNSStudy shows Tristel Wipes System benefits
20th Sep 20167:00 amRNSNotice of Results
19th Sep 20169:24 amRNSIssue of Equity
12th Sep 20167:00 amRNSRegulatory approval in Australia for surface range
19th Aug 20164:30 pmRNSDirector/PDMR Shareholding
19th Aug 20161:30 pmRNSIssue of Equity
21st Jul 20163:26 pmRNSDirector Dealing
21st Jul 20167:00 amRNSTrading update, Special dividend & Acquisition
25th May 20167:00 amRNSShareholder Open Day & Notice of Trading Update
29th Apr 201611:06 amRNSDirector Dealing
26th Apr 201610:06 amRNSDirector Dealing
15th Mar 20167:00 amRNSDirector Dealing
11th Mar 20167:00 amRNSDirector Dealing
10th Mar 20167:00 amRNSDirector Dealing
2nd Mar 20165:13 pmRNSDirector Dealing
2nd Mar 20169:46 amRNSDirector Dealing
29th Feb 20167:00 amRNSDirector Dealing
26th Feb 20169:43 amRNSDirectors Dealings
24th Feb 20167:00 amRNSHalf Yearly Report
25th Jan 20167:00 amRNSNotice of Results
13th Jan 20164:53 pmRNSIssue of Equity
5th Jan 20167:00 amRNSTransition of German branch to subsidiary status
15th Dec 20151:43 pmRNSDirectors Dealings
15th Dec 201512:18 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.